Scientific Resources
Cytotron RFQMR-FRB therapy is supported by a growing body of peer-reviewed research, clinical trial data, and regulatory evaluations conducted over more than two decades. This page collects key published studies and resources for patients, families, and referring physicians.
Title: U.S. FDA Breakthrough Device Designation — Cytotron
Date: 24 October 2019
Oncology
The U.S. FDA granted Breakthrough Device Designation for the treatment of Breast, Liver, and Pancreatic cancers — signifying the Cytotron’s potential to offer more effective care for life-threatening conditions.
Title: Overall Survival in Terminal Solid Tumours Following QMRT
Oncology
Pilot study of 98 terminally ill cancer patients. Statistically significant extension of lifespan (p = 2.13 × 10⁻¹²). 71% achieved stable disease at one month. Significant improvement in Karnofsky Performance Scale and Quality of Life scores.
Title: Cartilage Regeneration in Knee Osteoarthritis Using RFQMR
Author: Vasishta et al. (2004); Technology Evaluation Programme (380 knee joints)
Musculoskeletal
Demonstrated highly significant increase in cartilage thickness from 0.64 mm to 0.88 mm at 90 days post-treatment (P < 0.001). Significant pain reduction and increased range of motion.
Title: Efficacy of RFQMR in Promoting Remyelination in Multiple Sclerosis
Registry: ClinicalTrials.gov NCT01220830
Neurology
Clinical trial evaluating Cytotron’s capacity to stimulate oligodendrocyte synthesis of Connexin 32 for remyelination in MS patients. Monitored via MRI FLAIR sequences and EDSS scoring.
Title: Safety and Efficacy of QMRT in Terminal Paediatric Brain Tumours
Hospital Infantil de Mexico Federico Gomez
ClinicalTrials.gov NCT03577600
Oncology
Evaluated safety and efficacy of QMRT in terminal paediatric brain tumours. Statistically significant increase in overall survival compared to historical controls. 40% of patients survived beyond the three-year follow-up mark.